Table 2.
Demographic, clinic and laboratory features of the subjects according to AIP risk groups
| Parameters | Low Risk (AIP < 0.11) (n = 229) | Intermediate Risk (AIP = 0.11-0.21) (n = 88) | Increased Risk (AIP > 0.21) (n = 328) | P value |
|---|---|---|---|---|
| Female/Male (n/n)* | 127/102 | 48/40 | 125/203 | < 0.001 |
| Age (years)** | 60 (52-69) | 61 (54-70) | 59 (51-66) | > 0.05 |
| Creatinine (mg/dL)** | 0.83 (0.76-0.92) | 0.83 (0.76-0.92) | 0.88 (0.79-1.02) | < 0.001 |
| Uric Acid (mg/dL)*** | 5.3 ± 1.4 | 5.4 ± 1.3 | 5.8 ± 1.4 | < 0.001 |
| Albuminuria (mg/gr Cr)** | 7.05 (3.10-19.60) | 8.21 (2.88-36.08) | 12.65 (4.20-59.71) | < 0.001 |
| HbA1c (%)** | 6.9 (5.9-8.2) | 7.3 (6.1-8.9) | 7.5 (5.7-9.3) | < 0.001 |
| TSH (U/mL)** | 1.25 (0.85-1.81) | 1.42 (0.92-2.04) | 1.36 (0.79-1.97) | > 0.05 |
*
Chi-square test;
**
Kruskal Wallis Test [Median (IQR)];
***
Oneway ANOVA Test (Mean ± SD).
AIP: Atherogenic Index of Plasma, HbA1c: Glycosylated Hemoglobin, TSH: Thyroid Stimulating Hormone.